Researchers evaluated high- and intermediate-dose bevacizumab for the treatment of type 1 retinopathy of prematurity in premature infants.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results